Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim

References

• Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103(9):1916–1924.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Hematopoietic growth factors. Version 2.2019-March 27, 2019; [cited 2019 May 21]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf.
   Google Scholar
• Crawford J, Dale DC, Kuderer NM, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw. 2008;6(2):109–118.
   PubMedGoogle Scholar
• Barnes G, Pathak A, Schwartzberg L. G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use. Cancer Med. 2014;3(6):1477–1484.
   PubMed Web of Science ®Google Scholar
• Hirsch BR, Lyman GH. Pharmacoeconomics of the myeloid growth factors: a critical and systematic review. Pharmacoeconomics. 2012;30(6):497–511.
   PubMed Web of Science ®Google Scholar
• Wang XJ, Lopez SE, Chan A. Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review. Crit Rev Oncol Hematol. 2015;94(2):201–212.
   PubMed Web of Science ®Google Scholar
• Michels SL, Barron RL, Reynolds MW, et al. Costs associated with febrile neutropenia in the US. Pharmacoeconomics. 2012;30(9):809–823.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258–2266.
   PubMed Web of Science ®Google Scholar
• Tai E, Guy GP, Dunbar A, et al. Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. J Oncol Pract. 2017;13(6):e552–e561.
   PubMed Web of Science ®Google Scholar
• Aapro M, Cornes P, Sun D, et al. Comparative cost-efficiency across the European Union G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in cancer patients. Ther Adv Med Oncol. 2012;4(3):95–105.
   PubMed Web of Science ®Google Scholar
• Aapro M, Cornes P, Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract. 2012;18(2):171–179.
   PubMedGoogle Scholar
• Abraham I, Han L, Sun D, et al. Cost savings from anemia management with biosimilar epoetin α and increased access to targeted antineoplastic treatment: simulation for the European G5 countries. Fut Oncol. 2014;10(9):1599–1609.
   PubMed Web of Science ®Google Scholar
• Sun D, Andayani TM, Altyar A, et al. Potential cost savings from chemotherapy-induced febrile neutropenia prophylaxis with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European G5 countries: a simulation study. Clin Ther. 2015;37(4):842–857.
   PubMed Web of Science ®Google Scholar
• McBride A, Campbell K, Bikkina M, et al. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ. 2017;20(10):1083–1093.
   PubMed Web of Science ®Google Scholar
• McBride A, Balu S, Campbell K, et al. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. Fut Oncol. 2017;13(25):2285–2295.
   PubMed Web of Science ®Google Scholar
• McBride A, Campbell K, Bikkina M, et al. Reply: cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ. 2018;21(6):606–609.
   PubMed Web of Science ®Google Scholar
• Blackwell K, Donskih R, Jones CM, et al. A comparison of proposed biosimilar LA-EP2006 and reference pegfilgrastim for the prevention of neutropenia in patients with early-stage breast cancer receiving myelosuppressive adjuvant or neoadjuvant chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a phase III, randomized, double-blind trial. Oncologist. 2016;21(7):789–794.
   PubMed Web of Science ®Google Scholar
• Harbeck N, Lipatov O, Frolova M, et al. Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. Fut Oncol. 2016;12(11):1359–1367.
   PubMed Web of Science ®Google Scholar
• McBride A, Krendyukov A, Mathieson N, et al. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma. J Med Econ. 2020;23(1):28–36.
   PubMed Web of Science ®Google Scholar
• ASP Drug Pricing Files April 2019. Update. Center for Medicare and Medicaid Services; [cited 2019 Apr 14]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2019ASPFiles.html.
   Google Scholar
• Pegfilgrastim and pegfilgrastim-bmez. Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI; [cited 2019 Dec 22]. Available from: http://www.micromedexsolutions.com.
   Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy- induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.
   PubMed Web of Science ®Google Scholar
• Gascón P, Aapro M, Ludwig H, et al. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (the MONITOR-GCSF study). Support Care Cancer. 2016;24(2):911–925.
   PubMed Web of Science ®Google Scholar
• Aapro M, Ludwig H, Bokemeyer C, et al. Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study). Ann Oncol. 2016;27(11):2039–2045.
   PubMed Web of Science ®Google Scholar